Trial Profile
Randomized, Doubleblind, Placebo-controlled Trial in Healthy Adults of Safety and Immunogenicity of 2 Intranasal Doses of SynGEM, an RSV Candidate Vaccine Containing F Glycoprotein Linked to a Bacterium-like-Particle (BLP) Carrier
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Respiratory syncytial virus vaccine-Virtuvax (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors Mucosis
- 13 Feb 2019 According to a Virtuvax media release, clinical data from the study were published online in the American Journal of Respiratory and Critical Care Medicine.
- 12 Feb 2019 Results assessing safety and immunogenecity published in the American Journal of Respiratory and Critical Care Medicine.
- 07 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.